Also learn about Oncodesign Services, dedicated to CRO activities in Drug Discovery

Learn more
Oncodesign Precision Medicine Stand with Ukraine

Also learn about Oncodesign Services, dedicated to CRO activities in Drug Discovery

Learn more
  • Our pipeline
    • Partnering
  • Our innovation technologies
    • OncoSNIPER
    • Nanocyclix
    • PROMETHE
  • Investors
    • Message from the chairman
    • Regulated information [FR]
    • Press Release
    • General Meetings [FR]
  • About us
    • Latest news
    • Our history
    • Management
    • Our HR policy
    • Our CSR approach
    • FederAidd
  • Contact us
  • Français
  • English

Posts

  • You are currently browsing the Oncodesign Precision Medicine blog archives for April 2023.

  • Pages

    • About us
      • Careers
      • FederAidd
      • Management
      • News
      • Our CSR approach
      • Our history
    • Contact us
    • Home
    • Investors
      • Message from the chairman
      • Regulated information [FR]
    • Legal notice
    • Our innovation technologies
      • Nanocyclix
      • OncoSNIPER
      • Theranostics
    • Our pipeline
      • Partnering
    • Personal data policy
    • Press Release
    • Thank you for signing up to our newsletter
    • Thank you for your message.

  • Archives

    • September 2023
    • May 2023
    • April 2023
    • February 2023
    • December 2022
    • October 2022
    • September 2022
    • July 2022
    • June 2022
    • March 2022
    • February 2022
    • January 2022
    • October 2021
    • June 2021
    • May 2021
    • September 2020
    • October 2019

  • Categories

    • Financial (6)
    • News (12)
    • Poster (3)
    • Press Release (15)
    • Scientific paper (4)
    • Uncategorized (2)
Oncodesign Precision Medicine
  • Our innovation technologies
    • OncoSNIPER
    • Nanocyclix
    • PROMETHE
  • Our pipeline
  • Latest News
  • About us
  • Investors
  • Contact us

Newsletter

  • Legal notice
  • Personal data policy